| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-08-04 | Inovio Pharmaceuticals (USA - PA) | nomination |
Cancer - Oncology - Infectious disease | Nomination | ||
| 2016-08-04 | Jacobs Engineering Groupe (USA - CA) Alnylam Therapeutics (USA - MA) | new manufacturing facility supplying RNA interference-based therapeutics | construction of new premises services contract |
Technology - Services | Construction of new premises | |
| 2016-08-03 | Roche (Switzerland) Inovio Pharmaceuticals (USA - PA) | multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B (INO-5150, INO-1800) and CELLECTRA® electroporation technology | hepatitis B, cancer | R&D |
Cancer - Oncology - Infectious diseases | Termination of an agreement |
| 2016-08-03 | Philogen (Italy) Janssen Biotech, a J&J company (USA - NJ) | new class of immunomodulatory therapeutics | collaboration licensing |
Licensing agreement | ||
| 2016-08-02 | Catalyst Biosciences (USA - CA) Attenua (USA) | oral Neuronal Nicotinic Receptor (NNR) assets | product acquisition |
CNS diseases - Respiratory diseases - Rare diseases | Product acquisition | |
| 2016-08-02 | Kyowa Hakko Kirin (Japan) | HB6 Plant | construction of a production plant |
Technology - Services | Construction of a production plant | |
| 2016-08-02 | Regeneron Pharmaceuticals (USA - NY) Adicet Bio (USA - CA) | engineered immune cell therapeutics | hematological cancers and solid tumor cancers | licensing collaboration |
Cancer - Oncology | Licensing agreement |
| 2016-08-02 | Amgen (USA - CA) Advaxis (USA - NJ) | ADXS-NEO | developement commercialisation |
Cancer - Oncology | Development agreement | |
| 2016-08-02 | Plasticell (UK) National University of Ireland, Galway (NUI Galway) (Ireland) | combinations of drugs, growth factors and chemotherapeutic agents | leukemia | R&D -research | Cancer - Oncology | R&D agreement |
| 2016-08-02 | Recordati (Italy) Gedeon Richter (Hungary) | cariprazine | schizophrenia, bipolar disorder | licensing | CNS diseases - Mental diseases | Licensing agreement |
| 2016-08-01 | GSK (UK) Verily Life Sciences (USA - CA) Galvani Bioelectronics (UK) | bioelectronic medicines | establishment of a new subsidiary in the EU |
Endocrinological diseases - Hormonal diseases - Inflammatory diseases - Metabolic diseases | Establishment of a new subsidiary in the EU | |
| 2016-08-01 | BiolineRx (Israel) Hadasit, the Technology Transfer Company of Hadassah Medical Organization (Israel) | BL-1210 | liver fibrosis, non-alcoholic steatohepatitis (NASH) | licensing |
Liver diseases - Hepatic diseases | Licensing agreement |
| 2016-07-29 | Takeda Pharmaceutical (Japan) | restructuring |
Cancer - Oncology - Gastrointestinal diseases - Digestive diseases - CNS diseases - Infectious diseases | Restructuring | ||
| 2016-07-29 | Diamyd Medical (Sweden) Janssen Research & Development, a J&J company (USA - NJ) the Juvenile Diabetes Research Foundation (JDRF) (USA) the University of Alabama at Birmingham (USA) | type 1 diabetes | clinical research |
Autoimmune diseases - Metabolic diseases | Clinical research agreement | |
| 2016-07-28 | Oxford Biomedica (UK) | biomanufacturing facility for cell and gene therapy products | validation of a production plant |
Regenerative Medicine | Validation of a production plant | |
| 2016-07-28 | Jazz Pharmaceuticals (Ireland) Pfenex (USA - CA) | early stage hematology product candidates including a recombinant pegaspargase product candidate | development commercialisation |
Hematologic diseases - Genetic diseases - Rare diseases | Development agreement | |
| 2016-07-27 | Servier (France) | bioproduction program at Gidy | construction of new premises |
Technology - Services | Construction of new premises | |
| 2016-07-27 | Onxeo (France) Pint Pharma (Switzerland) | Beleodaq® (belinostat) | peripheral T-cell lymphoma (PTCL) | licensing commercialisation | Cancer - Oncology | Commercialisation agreement |
| 2016-07-27 | Sun Pharmaceutical Industries (India) Almirall (Spain) | tildrakizumab | psoriasis | licensing - development - commercialisation | Autoimmune diseases - Dermatological diseases - Inflammatory diseases | Licensing agreement |
| 2016-07-27 | Neon Therapeutics (USA - MA) | nomination | Cancer - Oncology | Nomination |
